Numerous pharmaceutical and biotechnology candidates remain under formal review by the U.S. Food and Drug Administration, spanning novel cancer immunotherapies, rare disease gene therapies, cardiovascular medications, and expanded biosimilar applications. Regulatory review timelines depend on whether compounds received breakthrough therapy designations or priority review status from federal agencies.